Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganzhixiao Capsules for Metabolic Associated Fatty Liver Disease
NCT06848907Phase 2Not yet recruiting
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 2, randomised, double-blind trial in metabolic associated fatty liver disease (MAFLD) comparing Ganzhixiao Group with Placebo Group (2 arms). Primary endpoint: Magnetic Resonance Imaging Proton Density Fat Fraction at 16 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
Ganzhixiao
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT06848907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848907.